Richard Drury/DigitalVision via Getty Images Investment Overview The stock of Ascendis Pharma ( ASND ) has risen in value by >1,000% over the past decade, climbing from a price of ~$20, to >$235 per share at the time of writing. Stock is also up >85% on a 1-year basis. I first covered Ascendis in a note for Seeking Alpha in April 2023, awarding stock a Buy rating with stock trading at ~$72 per sha...
Richard Drury/DigitalVision via Getty Images Investment Overview The stock of Ascendis Pharma ( ASND ) has risen in value by >1,000% over the past decade, climbing from a price of ~$20, to >$235 per share at the time of writing. Stock is also up >85% on a 1-year basis. I first covered Ascendis in a note for Seeking Alpha in April 2023, awarding stock a Buy rating with stock trading at ~$72 per share, having collapsed in value after a delay to the FDA's regulatory review for commercial approval of TransCon PTH (palopegteriparatide) in hypoparathyroidism. As a reminder, re its Q3 2025 quarterly report / 10Q filing : Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drug’s action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability, and convenience. In addition to retaining the original mode of action of the parent drug and potentially supporting dosing frequency from daily up to six months or more, we believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits. By the time of my next note, Ascendis stock traded at $193 per share, justifying my Buy call. Ultimately, after a delay, TransCon PTH was approved in August 2024, and is also approved in Europe. It is the second product Ascendis has commercialised, and is marketed and sold as Yorvipath. Skytrofa (TransCon hGH) has also been approved to treat growth hormone deficiency, since 2021. Announcing its Q3 earnings and business updates last November 12th, Ascendis revealed revenues of €143.1 million for YORVIPATHand €50.7 million for SKYTROFA. On a nine-month basis, the company reported $443.5m of total commercial product revenue, total revenues of $472.6m, a net loss of...
Richard Drury/DigitalVision via Getty Images Investment Overview The stock of Ascendis Pharma ( ASND ) has risen in value by >1,000% over the past decade, climbing from a price of ~$20 to >$235 per share at the time of writing. Stock is also up >85% on a 1-year basis. I first covered Ascendis in a note for Seeking Alpha in April 2023, awarding the stock a Buy rating with the stock trading at ~$72 ...
Richard Drury/DigitalVision via Getty Images Investment Overview The stock of Ascendis Pharma ( ASND ) has risen in value by >1,000% over the past decade, climbing from a price of ~$20 to >$235 per share at the time of writing. Stock is also up >85% on a 1-year basis. I first covered Ascendis in a note for Seeking Alpha in April 2023, awarding the stock a Buy rating with the stock trading at ~$72 per share, having collapsed in value after a delay to the FDA's regulatory review for commercial approval of TransCon PTH (palopegteriparatide) in hypoparathyroidism. As a reminder, re its Q3 2025 quarterly report / 10-Q filing : Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drug’s action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability, and convenience. In addition to retaining the original mode of action of the parent drug and potentially supporting dosing frequency from daily up to six months or more, we believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits. By the time of my next note, Ascendis stock traded at $193 per share, justifying my Buy call. Ultimately, after a delay, TransCon PTH was approved in August 2024 and is also approved in Europe. It is the second product Ascendis has commercialised, and is marketed and sold as Yorvipath. Skytrofa (TransCon hGH) has also been approved to treat growth hormone deficiency since 2021. Announcing its Q3 earnings and business updates last November 12th, Ascendis revealed revenues of €143.1 million for YORVIPATH and €50.7 million for SKYTROFA. On a nine-month basis, the company reported $443.5m of total commercial product revenue, total revenues of $472.6m, a net ...
From sector tilts to portfolio concentration, key differences between these ETFs could shape your approach to growth investing. The Vanguard Mega Cap Growth ETF (MGK +0.59%) and the iShares Russell 2000 Growth ETF (IWO 1.96%) both track U.S. growth stocks, but their approaches diverge: MGK concentrates on the nation’s largest, fastest-growing companies, while IWO targets growth names from the smal...
From sector tilts to portfolio concentration, key differences between these ETFs could shape your approach to growth investing. The Vanguard Mega Cap Growth ETF (MGK +0.59%) and the iShares Russell 2000 Growth ETF (IWO 1.96%) both track U.S. growth stocks, but their approaches diverge: MGK concentrates on the nation’s largest, fastest-growing companies, while IWO targets growth names from the small-cap end of the market. This comparison breaks down the two funds across cost, performance, risk, and portfolio construction to help investors decide which may best fit their strategy. Snapshot (cost & size) Metric MGK IWO Issuer Vanguard iShares Expense ratio 0.07% 0.24% 1-yr return (as of Jan. 25, 2026) 15.25% 15.35% Dividend yield 0.35% 0.56% Beta (5Y monthly) 1.20 1.45 AUM $32 billion $13 billion IWO charges a noticeably higher expense ratio than MGK, though IWO’s yield edges slightly higher for those seeking a bit more income from a growth ETF. Performance & risk comparison Metric MGK IWO Max drawdown (5 y) -36.02% -42.02% Growth of $1,000 over 5 years $1,954 $1,097 What's inside IWO delivers exposure to over 1,000 small-cap U.S. growth stocks, with a sector tilt toward healthcare (making up 26% of assets), technology (23%), and industrials (20%). Its largest positions include Bloom Energy, Credo Technology Group, and Kratos Defense & Security Solutions, and each represents less than 2% of the portfolio. Launched over 25 years ago, IWO may appeal to investors looking for long-term access to innovative smaller companies. MGK, by contrast, is built around mega-cap growth. It contains only 60 stocks, with technology making up 55% of the fund. Its top holdings — Nvidia, Apple, and Microsoft — dominate the portfolio, resulting in a more concentrated bet on the largest and most established growth names in the U.S. market. For more guidance on ETF investing, check out the full guide at this link. What this means for investors MGK and IWO take drastically different approaches...
Nidec Corp. will release a plan this week to get its business back on track, people familiar with the matter say, after an accounting scandal that has put the company at risk of delisting and caused its debt to be downgraded to junk status. The plan will be announced as soon as Wednesday and will include revisions to past financial results, more details on how the issues came to light and the step...
Nidec Corp. will release a plan this week to get its business back on track, people familiar with the matter say, after an accounting scandal that has put the company at risk of delisting and caused its debt to be downgraded to junk status. The plan will be announced as soon as Wednesday and will include revisions to past financial results, more details on how the issues came to light and the steps that will be taken to prevent a repeat, said one of the people, who asked not to be identified because the information isn’t public. While the initiative marks one step toward recovery since founder Shigenobu Nagamori stepped down from the board in December, a third-party probe into accounting issues is still underway and could reveal more details. Nagamori’s growth-at-all-costs approach is under scrutiny following a growing number of suspected cases of improper accounting, which have triggered filing delays, credit downgrades and the risk of delisting in Tokyo. A representative for Nidec declined to comment. Read More: Nidec Chairman Quits Board After Spate of Accounting Issues The plan will take aim at untangling the more damaging aspects of that legacy, including corporate culture and education on compliance as well as a reassessment of its business plan. Since June, Nidec repeatedly disclosed accounting issues that have spanned subsidiaries in Italy, Switzerland and China. The cases have bogged down auditors’ assessment of the company’s finances, delaying submission of its financial reports. The Tokyo Stock Exchange has put Nidec on notice for a potential delisting, unless it can erase concerns over corporate governance. Moody’s Ratings downgraded the company while warning that further risks remained. The stock has also been removed from the benchmark Nikkei 225 index. Its shares are down 30% since late August. Nagamori was replaced by Chief Executive Officer Mitsuya Kishida . A few months earlier, Nidec had launched a third-party committee to investigate the origin a...
(RTTNews) - Samsung Electronics Co. (SSNLF, 005930.KS, SMSN.L, 005935.KS) is nearing certification from Nvidia Corp. for its next-generation AI memory chip, HBM4, according to media reports citing people familiar with the matter. The Suwon, South Korea-based company has advanced to the final qualification stage with Nvidia after providing initial samples to the U.S. chipmaker in September. As Nvid...
(RTTNews) - Samsung Electronics Co. (SSNLF, 005930.KS, SMSN.L, 005935.KS) is nearing certification from Nvidia Corp. for its next-generation AI memory chip, HBM4, according to media reports citing people familiar with the matter. The Suwon, South Korea-based company has advanced to the final qualification stage with Nvidia after providing initial samples to the U.S. chipmaker in September. As Nvidia depends heavily on high-bandwidth memory (HBM) to power its AI accelerators, the certification represents a crucial milestone. Samsung is preparing to launch mass production of HBM4 in February, the reports said. The company is expected to be ready for shipments soon, although the precise timing of deliveries has not yet been determined. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.